Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

David P. Steensma, Rafael Bejar, Siddhartha Jaiswal et al. · Blood · 2015 · 1.9K citations · Full text

Medicine, Hematology, Pathology +16

VarSome: the human genomic variant search engine

Christos Kopanos, Vasilis Tsiolkas, Alexandros Kouris et al. · Bioinformatics · 2018 · 1.9K citations · Full text

Life Sciences, Bioinformatics, Genetics +14

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

Medicine, Hematology, Hematopathology +9

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym et al. · Blood · 2015 · 1.1K citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +2